PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|PROCEDURE: Therapeutic Conventional Surgery|DRUG: Triciribine Phosphate
Sponsor: Prescient Therapeutics, Ltd.
Collaborators: National Cancer Institute (NCI)